SPRB
SPRUCE BIOSCIENCES, INC.Company Information
- Company Name
- SPRUCE BIOSCIENCES, INC.
- CIK
- CIK0001683553
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- SPRB: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- SPRB
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-10-06
- Last sale
- 2025-10-06
- Shares purchased (TTM)
- 512
- Shares sold (TTM)
- 514
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 2,008,845
- Shares outstanding
- 2,431,075
- Ownership
- 82.63%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- 23.07%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Series A Redeemable Preferred Stock | - | - | - | - | 0 | - | - | - | - | - | - | - | ||||||
| Cash And Cash Equivalents At Carrying Value | 96 | 54 | 49 | 11 | 16 | 26 | 39 | 60 | 70 | 81 | 96 | 99 | ||||||
| Prepaid Expense Current | 5 | 1 | 0 | 1 | 2 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | ||||||
| Other Assets Current | 0 | 0 | 3 | 3 | 3 | 2 | 2 | 1 | 2 | 2 | 2 | 0 | ||||||
| Short Term Investments | - | - | - | - | - | - | - | - | - | - | 0 | 9 | ||||||
| Assets Current | 101 | 55 | 52 | 15 | 21 | 31 | 44 | 64 | 74 | 86 | 102 | 111 | ||||||
| Other Assets Noncurrent | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 103 | 56 | 53 | 15 | 22 | 32 | 45 | 65 | 76 | 88 | 104 | 113 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accrued Liabilities Current | - | - | - | - | - | - | - | 8 | 11 | - | - | - | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 3 | 1 | 1 | 1 | 2 | 1 | 2 | 1 | 2 | 3 | 3 | ||||||
| Deferred Revenue Current | - | - | - | - | - | - | 0 | 1 | 1 | 3 | 5 | 8 | ||||||
| Long Term Debt Current | 3 | 1 | 0 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Liabilities Current | 11 | 12 | 10 | 9 | 8 | 16 | 15 | 12 | 14 | 18 | 24 | 24 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 1 | 1 | 1 | 1 | - | - | 1 | 1 | - | ||||||
| Long Term Debt Noncurrent | 5 | 5 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 2 | ||||||
| Other Liabilities Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Derivative Liabilities Noncurrent | 3 | 4 | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities | 19 | 22 | 11 | 10 | 9 | 16 | 16 | 13 | 16 | 21 | 27 | 28 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 401 | 336 | 332 | 280 | 280 | 280 | 279 | 278 | 277 | 275 | 274 | 273 | ||||||
| Retained Earnings Accumulated Deficit | -318 | -302 | -289 | -275 | -266 | -264 | -250 | -227 | -218 | -209 | -197 | -187 | ||||||
| Stockholders Equity | 84 | 35 | 43 | 5 | 13 | 15 | 29 | 52 | 59 | 67 | 77 | 85 | ||||||
| Liabilities And Stockholders Equity | 103 | 56 | 53 | 15 | 22 | 32 | 45 | 65 | 76 | 88 | 104 | 113 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | - | - | - | - | - | - | - | - | - | 0 | -0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Shares Outstanding | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialSPRUCE BIOSCIENCES, INC. (SPRB) — SEC Financial Statements & Analysis
SPRUCE BIOSCIENCES, INC. (SPRB) is a pharmaceutical preparations company, incorporated in DE. SPRUCE BIOSCIENCES, INC. trades on Nasdaq as: SPRB. SPRUCE BIOSCIENCES, INC. (SPRB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, SPRUCE BIOSCIENCES, INC. carries a market cap of $131.28M, a P/E ratio of -2.56x, a P/B ratio of 1.57x, a P/S ratio of 7.23x, an enterprise value of $42.04M, and an EV/EBITDA multiple of -0.90x. On profitability, it posts a gross margin of 106.25%, an operating margin of -7100.00%, a net margin of -6869.30%, a Return on Equity (ROE) of -105.98%, a Return on Assets (ROA) of -82.38%, and a Return on Invested Capital (ROIC) of -212.33%. Per share, it reports EPS of $-21.12, diluted EPS of $-21.12, free cash flow per share of $-17.59, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 6.24% year-over-year, and EPS growth of -74.17% year-over-year. On the balance sheet, it maintains a current ratio of 9.23x, a quick ratio of 8.80x, working capital of $90.19M, a debt-to-equity ratio of 0.23x, a debt ratio of 0.19, an interest coverage ratio of -26.63x, free cash flow of $-42.77M (TTM), and net debt of $-89.24M. Figures sourced from SEC EDGAR.
- Market Cap
- $131.28M
- P/E TTM
- -2.56x
- EPS TTM
- $-21.12
- P/B TTM
- 1.57x
- ROE TTM
- -105.98%
- ROA TTM
- -82.38%
- Debt To Equity
- 0.23x
- Free Cash Flow TTM
- $-42.77M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is SPRUCE BIOSCIENCES, INC. in?
SPRUCE BIOSCIENCES, INC. (SPRB) operates in the Pharmaceutical Preparations industry.
What exchange does SPRB trade on?
SPRUCE BIOSCIENCES, INC. (SPRB) trades on the Nasdaq.
Where is SPRUCE BIOSCIENCES, INC. incorporated?
SPRUCE BIOSCIENCES, INC. is incorporated in DE.
When was SPRUCE BIOSCIENCES, INC. (SPRB)'s most recent SEC filing?
SPRUCE BIOSCIENCES, INC. (SPRB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is SPRB's market cap?
SPRUCE BIOSCIENCES, INC. (SPRB) has a market capitalization of $131.28M as of 2026-06-30.
What is SPRB's EPS (earnings per share)?
SPRUCE BIOSCIENCES, INC. (SPRB)'s trailing twelve month EPS is $-21.12 as of 2026-06-30.
What is SPRB's ROE (return on equity)?
SPRUCE BIOSCIENCES, INC. (SPRB)'s trailing twelve month Return on Equity (ROE) is -105.98% as of 2026-06-30.
What is SPRB's ROA (return on assets)?
SPRUCE BIOSCIENCES, INC. (SPRB)'s trailing twelve month Return on Assets (ROA) is -82.38% as of 2026-06-30.
What is SPRB's ROIC (return on invested capital)?
SPRUCE BIOSCIENCES, INC. (SPRB)'s trailing twelve month Return on Invested Capital (ROIC) is -212.33% as of 2025-12-31.
What is SPRB's EV/EBITDA?
SPRUCE BIOSCIENCES, INC. (SPRB)'s trailing twelve month EV/EBITDA is -0.90x as of 2026-06-30.